Abstract Background: In 2018, an innovative, State government‐funded cannabis medicines drug information service was established for health professionals in New…
Abstract Introduction: This phase I open-label study examined pharmacokinetics, safety, and tolerability of escalating doses of a novel combination cannabinoid…
Abstract Introduction: Despite increasing demand for data, little is known about the authorization patterns, safety, and effectiveness of medical cannabis…
Abstract The use of psychotropics during the COVID-19 pandemic has raised two questions, in order of importance: first, what changes…
Abstract Background: In 2017, the Jamaican government banned the sale of cannabis-infused edibles after reports of over-intoxication in adults and…
Abstract Objectives: The aim of this study was to determine the safety and tolerability of escalating doses of orally delivered…
Abstract Cannabidiol (CBD) is a biologically active, non-psychotropic component of Cannabis sativa whose popularity has grown exponentially in recent years.…
Abstract Over the past 5 years, public interest in the potential health benefits of cannabidiol (CBD) has increased exponentially, and…
Abstract Mutations in SYNGAP1 are associated with developmental delay, epilepsy, and autism spectrum disorder (ASD). Epilepsy is often drug‐resistant in…
Abstract Use of medical marijuana is increasing in the United States and older adults are the fastest growing user group.…